News & Events

Nerofe Pre-clinical Paper Published in Molecular and Clinical Oncology Journal

21 Oct|

Link To Article

ISK is going to the BIO conference 2016

29 Mar|

ISK was selected for the 6th time to represent Israel in the BIO conference which is being held this year in San-Francisco.

Nerofe’s Triple Action

01 Nov|

Nerofe causes ER stress to different type of cells
In Vitro assays have shown that Nerofe causes ER stress to cancer and endothelial cells, thus leading to cancer cell death and depletion of angiogenesis factors from serum, as seen in Phase Ia results. Because Immune cells express ST2 (Nerofe’s receptor), it is hypothesized

Breakthrough – Cancer Immunotherapy Effects of Nerofe

17 Sep|

NerofeTM stimulates cancer cells attraction to APC and T cells and thereby inducing the death of cancer cells.

Recent FACS results have shown a significant increase in CD86 expressing cells in three types of malignant cells treated with NerofeTM.

CD86 is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells,

ISK is going to the BIO conference 2015

23 Jun|

ISK was selected for the 5th time to represent Israel in the BIO conference in philadelphia

800,000 USD grant received from Chief scientist

03 May|

Preparing for Phase IIa

03 May|

Clinical trial: Phase I Dose Escalation completed successfully with exciting results

01 Apr|

To date, 23 patients with advanced/metastatic solid tumors have been enrolled (3+3 protocol).

Toxicity: MTD has not been reached. Treatment was well-tolerated with no cumulative toxicity.
Pharmacokinetic analysis: AUC, Cmax and t½ were calculated and were dose-dependent and approximately linear.
Efficacy: 5 of 15 evaluable patients have been treated for at least 3 cycles and were considered